Cases & Deals

Share

Galenica acquires Relypsa for $1.53 billion

September 2016

Client(s) Galenica AG

Jones Day advised Galenica AG, a diversified group of companies active throughout the health care market, in its acquisition of Relypsa, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of polymeric medicines, pursuant to a tender offer in which Galenica paid $32 per share, or a total of $1.53 billion.

In addition to M&A representation, Jones Day provided antitrust, employee benefits, and tax advice regarding this transaction.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.